Tango Therapeutics, Inc. TNGX
23.17 USD +1.41 (+6.48%)
At closeNov 3, 2026, 4:57 PM EST
23.17 0.00 0.00%
After hours · Nov 3, 4:57 PM ET
21.99 Day range 23.97
7.37 52-week range 34.39
- YTD
- +161.51%
- 1 year
- +189.26%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.09 +103.2% upside
Now 23.17
- Target (low)
- 24.00
- Target (mean)
- 47.09
- Target (high)
- 69.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy1
- Buy11
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 12
- 2 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.35083 | -0.42 – -0.30 | 0.13 | -369.9% | 0 | -100.0% | 12 |
| Next quarter | -0.375 | -0.46 – -0.31 | -0.29 | -29.3% | 0 | 0.0% | 12 |
| Current year | -1.40 | -1.57 – -1.17 | -0.87 | -60.3% | 0 | -100.0% | 12 |
| Next year | -1.69 | -2.23 – -1.24 | -1.40 | -20.8% | 2.62M | 0.0% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 12, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 17, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Jul 15, 2026 | JP Morgan | Initiated | — | Overweight |
| Jun 29, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 26, 2026 | Jefferies | Upgrade | Hold | Buy |
| Jun 11, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 9, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 9, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Jun 8, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| May 15, 2026 | Mizuho | Maintained | Outperform | Outperform |
| May 15, 2026 | Piper Sandler | Downgrade | Overweight | Neutral |
| May 14, 2026 | Jefferies | Downgrade | Buy | Hold |
| May 14, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| May 14, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 27, 2026 | Stifel | Maintained | Buy | Buy |
| Apr 2, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Mar 11, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Mar 9, 2026 | Stifel | Maintained | Buy | Buy |
| Mar 6, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 23, 2026 | Mizuho | Initiated | — | Outperform |
| Feb 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jan 16, 2026 | Piper Sandler | Maintained | Overweight | Overweight |
| Dec 4, 2025 | Stifel | Initiated | — | Buy |
| Nov 18, 2025 | Wolfe Research | Initiated | — | Peer Perform |
| Nov 18, 2025 | B. Riley Securities | Maintained | Buy | Buy |